Brendle et al. (2022) analyzed the cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the United States, utilizing clinical trial efficacy and real-world effectiveness estimates.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (4)

• ketamine concept
• U.S. location
• treatment-resistant depression concept
• esketamine concept